What is Mabt?
Mid-Atlantic BioTherapeutics (Mabt) is a biotechnology firm focused on developing innovative therapies for challenging neurological and infectious diseases, including Alzheimer's, Parkinson's, and ALS. The company recently expanded its oncology pipeline through the acquisition of XPose Therapeutics, aiming to deliver breakthrough treatments for difficult-to-treat cancers. By integrating biotechnology and artificial intelligence, Mabt is committed to addressing critical unmet medical needs and enhancing patient outcomes through compassionate innovation.
How much funding has Mabt raised?
Mabt has raised a total of $50M across 1 funding round:
Other Financing Round
$50M
Other Financing Round (2025): $50M with participation from Legend Innovators
Key Investors in Mabt
Legend Innovators
Legend Innovators, based in Bhubaneswar, Odisha, specializes in providing innovative business advisory services aimed at fostering sustainable growth for businesses of all sizes. Their core offerings include virtual CFO services, start-up mentoring, fund-raising services, and comprehensive business establishment support.
What's next for Mabt?
With this substantial capital infusion, Mabt is strategically positioned to accelerate its research and development initiatives, particularly in its oncology and neurodegenerative disease programs. The recent acquisition of XPose Therapeutics signals a clear intent to bolster its pipeline with high-impact cancer treatments. This major strategic investment will likely fuel further clinical trials, expand its AI-driven drug discovery capabilities, and potentially support market expansion efforts, solidifying its role as a key player in advancing novel therapeutic solutions.
See full Mabt company page
